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Summary 
Background: Studies that evaluated endocan levels in non-
alcoholic fatty liver disease (NAFLD) and liver fibrosis are
scarce. We aimed to explore endocan levels in relation to
different stages of liver diseases, such as NAFLD, as
determined with fatty liver index (FLI) and liver fibrosis, as
assessed with BARD score.
Methods: A total of 147 participants with FLI≥60 were
compared with 64 participants with FLI <30. An FLI score
was calculated using waist circumference, body mass
index, gamma-glutamyl transferase and triglycerides.
Patients with FLI≥60 were further divided into those with
no/mild fibrosis (BARD score 0–1 point; n=23) and
advanced fibrosis (BARD score 2–4 points; n=124). BARD
score was calculated as follows: diabetes mellitus (1 point)
+ body mass index≥28 kg/m2 (1 point) + aspartate
amino transferase/alanine aminotransferase ratio≥0.8 (2
points).
Results: Endocan was independent predictor for FLI and
BARD score, both in univariate [OR=1.255 (95% CI=
1.104–1.426), P=0.001; OR=1.208 (95% CI=1.029–
1.419), P=0.021, respectively] and multivariate binary
logistic regression analysis [OR=1.287 (95% CI=1.055–
1.570), P=0.013; OR=1.226 (95% CI=1.022–1.470),
Kratak sadr`aj
Uvod: Nema mnogo studija koje su ispitivale vrednosti
endokana kod obolelih od nealkoholne steatoze i fibroze
jetre. Na  cilj je bio da se ispita nivo endokana u razli~itim
stadijumima oboljenja jetre, kao to su nealkoholna
steatoza jetre, predstavljena indeksom masne jetre (FLI) i
fibroza jetre, predstavljena BARD skorom.
Metode: Ukupno 147 u~esnika sa FLI≥60 pore|eno je sa
64 u~esnika sa FLI <30. FLI skor je izra~unat koriste i
vrednosti obim struka, indeksa telesne mase, aktivnosti
gama-glutamil transferaze i vrednosti triglicerida. Ispitanici
sa FLI≥60 su dalje podeljeni u 2 grupe: bez fibroze/blaga
fibroza (BARD skor 0–1 poen; n=23) i uznapredovala
fibroza (BARD skor 2–4 poena; n=124). BARD skor je
ra~unat na slede i na~in: e erna bolest (1 poen) + indeks
telesne mase≥28 kg/m2 (1 poen) + odnos aspartat
aminotransferaza/alanin aminotransferaza≥0,8 (2 poena).
Rezultati: Endokan je nezavisan prediktor FLI i BARD
skora, kako u univarijantnoj [OR=1,255 (95% CI=1,104–
1,426), P=0,001; odnosno OR=1,208 (95% CI=1,029–
1,419), P=0,021], tako i u multivarijantnoj binarnoj lo -
gisti~koj regresionoj analizi [OR=1.287 (95% CI=1,055–
1,570), P=0,013; odnosno OR=1,226 (95% CI=1,022–
1,470), P=0,028]. Endokan kao samostalan prediktor
Unauthentifiziert   | Heruntergeladen  10.01.20 15:00   UTC
2 Klisi} et al.: Endocan in liver steatosis and fibrosis
Introduction 
Endocan is a proteoglycan with increased
expression in endothelial cells during even the first
stage of atheroslerosis (1), which makes this bio -
marker a convenient parameter of atherosclerosis
risk. Not only that it is secreted by endothelial cells,
but endocan also stimulates these cells to secrete
other inflammation markers (i.e. cytokines), con -
tributes to leukocytes migration, and has an impact
on permeability of blood vessels (2–4), all of which
further aggravate inflammation and increase
cardiovascular disease (CVD) risk burden.
In addition to CVD (1), higher levels of this
inflammation biomarker are also reported in states
with diminished insulin sensitivity, such as type 2
diabetes (5, 6), polycystic ovary syndrome (7), non-
alcoholic fatty liver disease (NAFLD) (8), which raises
the question whether endocan might represent the
link between inflammation in all these mentioned
disorders and CVD.
The NAFLD is the most frequent manifestation
of hepatic disorders (9). It represents the increased
accumulation of lipids which can trigger inflammation
(10), and lesions of hepatocytes, that can
consequently progress into fibrosis (11). Even more,
if not treated fibrosis can further progress into
cirrhosis and hepatocellular carcinoma (11).
Increased inflammation and oxidative stress are
observed in NAFLD (12–14). These patho physiolo -
gical mechanisms can stimulate the synthesis of
collagen and induce hepotocytes apoptosis (15).
Moreover, the impairment of lipids and lipoprotein
concentration was also shown in liver steatosis and
fibrosis (14, 16), paralell with the increased
prevalence of obesity and type 2 diabetes mellitus
(17–20).
On the other hand, endocan is not investigated
thoroughly in different stages of liver diseases, such
as NAFLD and liver fibrosis. Even more, a few studies
that examined the concentration of this biomarker in
fatty liver disease are conflicting (8, 21–23). Since
NAFLD represents an independent risk factor for CVD
(24), we aimed to explore serum endocan
concentration in relation to different stages of liver
diseases, such as NAFLD, as determined with fatty




This case-control study included a total of 147
participants with fatty liver diagnosed with FLI≥60,
who were compared with 64 controls, without fatty
liver (i.e., FLI <30). The participants were consecu-
tively recruited when visiting the Primary Health Care
Center in Podgorica, Montenegro, for evaluation of
metabolic parameters. The survey was conducted
during a period from May to July 2017.
The inclusion criteria for participants were
NAFLD diagnosed with FLI≥60 (25) with or without
type 2 diabetes. Diabetes was diagnosed by American
Diabetes Association Standards of Diabetes Care
(26). 
Algorithm FLI is calculated by waist circumfer-
ence (WC), body mass index (BMI), gamma-glutamyl
transferase (GGT) and triglycerides (TG) using equa-
tion (25): 
An FLI score is regarded to be a reliable algo-
rithm for NAFLD assessment in general population,
showing good specificity and sensitivity for NAFLD
when diagnosed by abdominal ultrasonography,
whereas FLI≥60 rules in, and FLI <30 rules out this
metabolic disorder (25, 27, 28).
P=0.028, respectively]. Endocan as a single predictor
showed poor discriminatory capability for steatosis/fibrosis
[AUC=0.648; (95% CI=0.568–0.727), P=0.002; AUC=
0.667 (95% CI=0.555–0.778), P=0.013, respectively],
whereas in a Model, endocan showed an excellent clinical
accuracy [AUC=0.930; (95% CI=0.886–0.975), P<0.001,
AUC=0.840 (95% CI=0.763–0.918), P<0.001, respec-
tively].
Conclusions: Endocan independently correlated with both
FLI and BARD score. However, when tested in models (with
other biomarkers), endocan showed better discriminatory
ability for liver steatosis/fibrosis, instead of its usage as a
single biomarker. 
Keywords: endocan, inflammation, liver steatosis, liver
fibrosis, cardiovascular disease
pokazao je slabu diskriminatornu mo  za steatozu/fibrozu
jetre [AUC=0,648; (95% CI=0,568–0,727), P=0,002;
odnosno AUC=0,667 (95% CI=0,555–0,778), P=0,013],
ali je u Modelu pokazao odli~nu klini~ku ta~nost
[AUC=0,930; (95% CI=0,886–0,975), P<0,001; od -
nosno AUC=0,840 (95% CI=0,763–0,918), P<0,001].
Zaklju~ak: Endokan je nezavisno povezan kako sa FLI, tako
i sa BARD skorom. Ipak, u modelu (sa drugim biomarkeri-
ma), endokan je pokazao bolju diskriminatornu sposobnost
za steatozu/fibrozu jetre. 
Klju~ne re~i: endokan, inflamacija, steatoza jetre,
fibroza jetre, kardiovaskularne bolesti
FLI = (e0.953 × loge (TG) + 0.139 × BMI + 0.718 × loge (GGT) 
+ 0.053 × WC − 15.745) /(1+e0.953 × loge (TG) + 0 .139 ×  BMI 
+ 0.718 × loge (GGT) + 0.053 × WC − 15.745) × 100.
Unauthentifiziert   | Heruntergeladen  10.01.20 15:00   UTC
J Med Biochem 2019; 38 3
Thereafter, only those participants with NAFLD
with FLI≥60 were further analyzed for potential liver
fibrosis. Namely, BARD score (29) was calculated as
follows: diabetes mellitus (1 point) + BMI≥28
kg/m2 (1 point) + aspartate aminotransferase (AST)/
alanine aminotransferase (ALT) ratio≥0.8 (2 points).
Harrison et al. (29) showed that a BARD score shows
a negative predictive value of 96% for liver fibrosis.
Accordingly, a total of 147 participants with
FLI≥60 were stratified into two groups: those with
no/mild fibrosis (i.e., BARD score 0–1 point; n=23)
and the others with advanced fibrosis (i.e., BARD
score 2–4 points; n=124).
Participants with 30≤ FLI <60, with alcohol
consumption (>20 g/day), malignant diseases, type
1 diabetes, with a history of acute myocardial infarc-
tion and/or stroke in the last 6 months, renal disease
other than diabetic nephropathy, thyroid dysfunction,
high sensitivity C-reactive protein (hsCRP) >10
mg/L, and pregnant women were excluded from the
examination.
Each participant signed an informed consent
and the study protocol was approved by the Ethics
Committee of the Primary Health Care Center in
Podgorica. The study was performed in conformance
with the Declaration of Helsinki ethical guidelines.
Anthropometric parameters (i.e., WC and BMI)
were obtained by the same healthcare professional.
The blood pressure was measured after the
patient’s rest for 5 minutes. The average of the 3
measurements with sphygmomanometer and taken
on the right arm was used.
Methods
The phlebotomy was done between 7: 00 and
10:00 a.m. after an over night fast of at least 8 hours.
Blood samples were taken in tubes with serum
separator and clot activator, and each sample was left
to clot within half an hour. Afterwards, the samples
were centrifuged at 3000xg, at room temperature for
10 minutes. Sera were divided into aliquots and
stored at -80 °C for determination of endocan and
hsCRP, whereas one aliquot of each serum was
analysed immediately after centrifugation for lipid
parameters [i.e., total cholesterol (TC), TG, low den-
sity lipoprotein cholesterol (LDL-c), and high density
lipoprotein cholesterol (HDL-c)], glucose, AST, ALT,
GGT and creatinine. All these parameters were
determined on Roche Cobas c501 chemistry analyzer
(Roche Diagnostics GmbH, Mannheim, Germany).
Serum endocan level was determined by using an
enzyme-linked immunosorbent commercial assay
(ab213776 – Human ESM1 ELISA Kit, Abcam,
Cambridge, UK), whereas serum hsCRP levels were
determined nephelometrically (Behring Nephelo -
meter Analyzer, Marburg, Germany).
Statistical analysis
Statistical analysis was done using SPSS 21.0
(SPSS Inc., Chicago, USA). Data distribution was
tested by Shapiro Wilk test. Continuous variables were
presented as median (interquartile range) and tested
by Mann-Whitney test. Categorical variables were
presented as absolute and relative frequencies and
analyzed using the Chi-square test for contingency
tables. Spearman’s correlation analysis (r) was
applied to examine the associations between FLI and
BARD score with the clinical data. Furthermore,
binary logistic regression analysis was applied in order
to test the independent associations of endocan with
FLI and BARD score. When performing logistic
regression analysis, FLI <30 was used as a reference
and FLI≥60 as risk categories, while BARD scores 0
and 1 point were used as reference (i.e., no/mild
fibrosis) and BARD scores 2, 3 and 4 points were
used as risk categories (i.e., advanced fibrosis).
Multivariate logistic regression analysis was used to
investigate possible independent predictions of
endocan on the presence of fatty liver, as well as on
advanced fibrosis. Data from binary logistic regres -
sion analysis were showed as odds ratio (OR) and
95% confidence interval (CI). Receiver operating
characteristic (ROC) analysis and the area under the
ROC curve (AUC) were used to test the predictive
ability of endocan, solely and in a model, for
identifying patients with fatty liver and advanced
fibrosis. Clinical accuracy of endocan was analysed
according to Swets (30). The P value less than 0.05
was considered as statistically significant.
Results
Clinical data of participants are summarized in
Table I. Significantly more men were found in the
group with fatty liver than in the group without it.
Individuals with fatty liver displayed greater BMI, WC,
as well as higher prevalence of type 2 diabetes, as
compared with individuals without fatty liver. More
subjects with fatty liver used antihyperglycemic,
insulin and antihypertensive therapy, than those
without fatty liver. Also, they had significantly higher
glucose, HbA1c, TG, ALT, GGT, hsCRP and endocan
levels, but lower HDL-c levels than individuals without
fatty liver.
The correlation coefficients from Spearman’s
correlation analysis between FLI and clinical data
were showed in Table II. BMI, WC, glucose, HbA1c,
TG, ALT, GGT and hsCRP showed positive, but HDL-
c negative correlations with FLI. 
Binary logistic regression analysis was applied to
determine in-depth associations of endocan and the
presence of fatty liver disease. In univariate analysis,
endocan showed significant relation with fatty liver
disease [OR=1.255 (95% CI=1.104–1.426),
P=0.001]. Negelkerke R2 in univariate regression
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Table I Clinical data and endocan levels in patients without and with fatty liver.
Data are given as median (interquartile range) and compared by Mann-Whitney test.
BMI – Body mass index; WC – Waist circumference; SBP – Systolic blood pressure; DBP – Diastolic blood pressure; FLI – Fatty
liver index; HbA1c – Glycated hemoglobin; TC – Total cholesterol; HDL-cholesterol – High density lipoprotein cholesterol; LDL-
cholesterol – Low density lipoprotein cholesterol; TG – Triglycerides; AST – Aspartate aminotransferase; ALT – Alanine
aminotransferase; GGT – Gamma-glutamyl transferase; HsCRP – High-sensitivity C-reactive protein 
Without fatty liver (FLI <30) Fatty liver (FLI≥60) P
N (male, %) 64 (14%) 147 (47%) <0.001
Age, years 60 (52–65) 62 (57–68) 0.051
BMI, kg/m2 24.1 (23.1–25.3) 31.6 (29.9–33.8) <0.001
WC, cm 85 (81–89) 105 (100–111) <0.001
SBP, mmHg 136 (126–151) 130 (125–145) 0.243
DBP, mmHg 86 (77–94) 83 (76–92) 0.345
Diabetes, n (%) 10 (16%) 75 (51%) <0.001
Smokers, n (%) 15 (23%) 23 (16%) 0.176
Antihyperglycemics, n (%) 7 (11%) 65 (44%) <0.001
Insulin therapy, n (%) 2 (3%) 22 (15%) 0.016
Antihypertensives, n (%) 31 (48%) 111 (76%) <0.001
Hypolipidemics, n (%) 18 (28%) 58 (39%) 0.122
FLI 16 (13–22) 83 (70–91) <0.001
Glucose, mmol/L 5.5 (5.3–5.8) 6.4 (5.5–8.3) <0.001
HbA1c, % 5.4 (5.2–5.7) 6.0 (5.5–7.2) <0.001
HbA1c, mmol/mol 36 (33–39) 42 (37–55) <0.001
TC, mmol/L 5.75 (4.75–6.54) 5.83 (4.87–6.93) 0.475
HDL-cholesterol, mmol/L 1.73 (1.53–2.03) 1.19 (1.00–1.40) <0.001
LDL-cholesterol, mmol/L 3.10 (2.52–4.025) 3.45 (2.62–4.53) 0.254
TG, mmol/L 1.17 (0.94–1.43) 2.25 (1.71–2.95) <0.001
AST, U/L 20 (17–23) 20 (17–24) 0.646
ALT, U/L 17 (11–22) 22 (17–32) <0.001
GGT, U/L 12 (9–16) 22 (16–31) <0.001
HsCRP, mg/L 0.52 (0.32–0.98) 1.70 (0.77–3.11) <0.001
Endocan, ng/L 27.8 (17.6–40.9) 38.8 (21.6–89.5) 0.002
Table II Spearman’s correlation analysis of clinical markers and FLI.
Data age given as coefficients of correlation Rho (r).
BMI-Body mass index; WC-Waist circumference; SBP-Systolic blood pressure; DBP-Diastolic blood pressure; HbA1c-Glycated
hemoglobin; TC-Total cholesterol; HDL-cholesterol-High density lipoprotein cholesterol; LDL-cholesterol-Low density
lipoprotein cholesterol; TG-Triglycerides; AST-Aspartate aminotransferase; ALT-Alanine aminotransferase; GGT-Gamma-
glutamyl transferase; HsCRP-High-sensitivity C-reactive protein 
Variable r P
Age, years 0.121 0.079
BMI, kg/m2 0.840 <0.001
WC, cm 0.902 <0.001
SBP, mmHg -0.038 0.578
DBP, mmHg -0.052 0.456
Glucose, mmol/L 0.435 <0.001
HbA1c, % 0.397 <0.001
TC, mmol/L -0.026 0.709
HDL-cholesterol, mmol/L -0.504 <0.001
LDL-cholesterol, mmol/L -0.028 0.685
TG, mmol/L 0.582 <0.001
AST, U/L 0.109 0.115
ALT, U/L 0.390 <0.001
GGT, U/L 0.639 <0.001
HsCRP, mg/L 0.413 <0.001
Endocan, ng/L 0.203 0.005
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analysis was 0.125. Markers significantly correlated
with FLI in non-parametric Spearman’s correlation
analysis (i.e., HbA1c, HDL-c, ALT, hsCRP and
endocan), but not used for FLI calculation, as well as
demographic characteristics significantly different
between FLI groups (i.e., gender, antihyperglycemic,
insulin and antihypertensive therapies) were used in
Model to test the independent prediction of endocan
for fatty liver disease. Endocan was shown to be an
independent predictor for fatty liver [OR=1.287
(95% CI=1.055-1.570), P=0.013]. Nagelkerke R2
of 0.656 demonstrated that even 65.6% of variation
in fatty liver disease occurrence could be explained by
this Model.
ROC analysis was used to discriminate patients
with fatty liver from those without fatty liver (Figure 1).
Endocan as a single predictor showed poor discrimi-
Figure 1 ROC curves of endocan and selected Model dis-
criminatory capabilities towards presence of fatty liver.
Table III Clinical data and endocan levels in patients without and with advanced fibrosis.
Data are given as median (interquartile range) and compared by Mann-Whitney test.
No/mild fibrosis Advanced fibrosis P
N (male, %) 23 (70%) 124 (43%) 0.018
Age, years 56 (51–61) 64 (58–70) <0.001
BMI, kg/m2 29.7 (28.1–33.3) 31.8 (30.3–34.3) 0.020
WC, cm 105 (99–107) 107 (101–112) 0.233
SBP, mmHg 139 (126–146) 130 (125–144) 0.586
DBP, mmHg 84 (80–92) 83 (76–90) 0.314
Diabetes, n (%) 4 (17%) 71 (57%) <0.001
Smokers, n (%) 5 (22%) 18 (15%) 0.381
Antihyperglycemics, n (%) 3 (13%) 62 (50%) 0.001
Insulin, n (%) 3 (13%) 19 (15%) 0.778
Antihypertensives, n (%) 12 (52%) 99 (80%) 0.005
Hypolipidemics, n (%) 8 (36%) 50 (40%) 0.618
Glucose, mmol/L 5.4 (5.2–6.1) 6.7 (5.8–8.5) <0.001
HbA1c, % 5.5 (5.3–5.9) 6.3 (5.6–7.3) 0.002
HbA1c, mmol/mol 37 (34–41) 45 (37–56) 0.002
TC, mmol/L 6.59 (5.04–7.79) 5.78 (4.87–5.79) 0.209
HDL-cholesterol, mmol/L 1.21 (1.01–1.32) 1.19 (0.99–1.34) 0.841
LDL-cholesterol, mmol/L 3.94 (3.07–4.86) 3.40 (2.60–4.37) 0.151
TG, mmol/L 2.36 (1.73–2.84) 2.20 (1.70–2.97) 0.821
AST, U/L 20 (19–24) 20 (17–25) 0.443
ALT, U/L 31 (25–39) 21 (16–28) <0.001
GGT, U/L 23 (16–35) 22 (15–30) 0.552
HsCRP, mg/L 1.81 (0.46–2.94) 1.67 (0.80–3.11) 0.362
Endocan, ng/L 26.0 (14.2–44.3) 44.2 (22.8–92.7) 0.013
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natory capability [AUC=0.648; (95% CI=0.568-
0.727), P=0.002]. Specificity of this test was
96.16%, but sensitivity was 34.78%. On the contrary,
when tested in the Model, endocan showed an excel-
lent clinical accuracy [AUC=0.930; (95% CI=0.886-
0.975)] with sensitivity of 90.58% and specificity of
86.54%.
Only patients with fatty liver (FLI≥60) were fur-
ther tested for possible presence of advanced fibrosis.
Their characteristics were given in Table III.
Significantly more women were found among those
with advanced than with no/mild fibrosis. Patients
with advanced fibrosis were older, had higher BMI,
and used frequently more antihyperglycemic and
antihypertensive therapies than those with no/mild
fibrosis. Also, significantly more of them had dia-
betes. Glucose, HbA1c, ALT and endocan levels were
higher in those with advanced fibrosis than in individ-
uals with no/mild fibrosis.
Years of age, glucose, HbA1c, and endocan cor-
related significantly positively with BARD score (Table
IV). On the contrary, ALT and TG correlated signifi-
cantly negatively with BARD score.
Binary logistic regression analysis was used to
test the associations of endocan with the presence of
advanced fibrosis. In univariate analysis odds ratio for
endocan was OR=1.208 (95% CI=1.029–1.419),
P=0.021, R2=0.088. In multivariate analysis, in the
Model that was consisted of gender, ages, TG, antihy-
pertensive therapy and endocan, the latest was shown
to be the independent predictor of advanced fibrosis
[OR=1.226 (95% CI=1.022–1.470), P=0.028].
Clinical markers that entered the Model were contin-
uous variables which showed significant correlation
with BARD score in Spearman’s correlation analysis
(Table IV) and categorical data significantly different
between no/mild vs. advanced fibrosis (Table III).
Nagelkerke R2 for the Model was 0.330 which shows
that 33% of variation in the presence of advanced
fibrosis could be explained by this Model.
Figure 2 ROC curves of endocan and selected Model dis-
criminatory capabilities towards presence of advanced fibro-
sis.
Table IV Spearman’s correlation analysis of clinical markers and BARD.
Data age given as coefficients of correlation Rho (r).
BMI – Body mass index; WC – Waist circumference; SBP – Systolic blood pressure; DBP – Diastolic blood pressure; HbA1c –
Glycated hemoglobin; TC – Total cholesterol; HDL-cholesterol – High density lipoprotein cholesterol; LDL-cholesterol – Low
density lipoprotein cholesterol; TG – Triglycerides; AST – Aspartate aminotransferase; ALT – Alanine aminotransferase; GGT –
Gamma-glutamyl transferase; HsCRP – High-sensitivity C-reactive protein 
Variable r P
Age, years 0.419 <0.001
BMI, kg/m2 0.145 0.080
WC, cm 0.052 0.529
SBP, mmHg 0.023 0.782
DBP, mmHg 0.017 0.842
Glucose, mmol/L 0.349 <0.001
HbA1c, % 0.307 <0.001
TC, mmol/L -0.142 0.085
HDL-cholesterol, mmol/L 0.148 0.074
LDL-cholesterol, mmol/L -0.142 0.086
TG, mmol/L -0.195 0.018
AST, U/L -0.049 0.522
ALT, U/L -0.461 <0.001
GGT, U/L -0.131 0.110
HsCRP, mg/L 0.062 0.457
Endocan, ng/L 0.217 0.010
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ROC analysis showed that curve for the Model
(Figure 2) had an excellent discriminatory capability
[AUC=0.840 (95% CI=0.763-0.918), P<0.001]
towards advanced fibrosis with specificity of 86.36%
and sensitivity of 72.41%. On the other hand, endo-
can itself has poor discriminatory ability towards
advanced fibrosis [AUC=0.667 (95% CI=0.555-
0.778), P=0.013] with specificity 81.82% and sensi-
tivity 46.55%.
Discussion
Our study shows that endocan levels were
higher in NAFLD (as assessed with FLI), as well as in
advanced fibrosis (as assessed with BARD score), as
compared with controls. Importantly, endocan inde-
pendently correlated with both, FLI and BARD score.
Only a small number of previous studies exam-
ined this biomarker in NAFLD, and showed contradic-
tory results (8, 21–23). Tok et al. (22) showed lower
endocan concentration in 38 patients with NAFLD,
whereas Dallilo et al. (8) reported vice versa (i.e., its
higher levels in 19 patients with NAFLD and 32 with
type 2 diabetes mellitus with NAFLD), as compared
with controls. On the contrary, Ustyol et al. (23)
found no difference in serum endocan levels between
obese participants with and without NAFLD, as
compared with controls in pediatric population.
Also, previous study (31) investigated serum
endocan in patients with liver cirrhosis and found only
higher level in patients with decompensated cirrhosis,
but no difference between compensated cirhhosis
and healthy controls was observed.
Additionally, another study showed that patients
with NAFLD and coronary artery disease displayed
higher serum endocan levels as compared with
patients with NAFLD, but without coronary artery
disease (21).
Possible discrepancies in those results might be
explained by the fact that sample size of participants
differed between the studies. In our study we included
a relatively larger sample size than previous studies
did (i.e., a total of 147 participants with NAFLD), and
only adult Caucasians (i.e., Montenegrin) population
(8, 22, 23). 
Endocan is highly expressed in endothelial cell
injury (1) with its up-regulation observed in the
presence of proangiogenic molecules and pro -
inflammatory cytokines (2). The pathological accu -
mulation of lipids in NAFLD triggers inflam mation
(10), which can lead to hepatocytes dysfunction.
Additionally, paralell with the liver fibrosis and with
the processes of its repairment, increased production
of extracellular matrix proteins occurs (11). Since
proteoglycans are constitute of the extracellular
matrix, acting as its structural components (32), this
might explain the higher level of endocan, as one of
the proteoglycans, in liver fibrosis.
Considering the fact that NAFLD is an indepen-
dent predictor for CVD (24), not only that endocan
might reflect the severity of liver failure, but further
prospective studies are necessary to explore the
causal link between high endocan level, liver
steatosis/fibrosis and CVD.
In our study median endocan level in patients
with NAFLD was 38.8 ng/L (21.6–89.5), whereas in
advanced fibrosis was 44.2 ng/L (22.8–92.7), as
compared with non-NAFLD group [median 27.8
ng/L (17.6–40.9)], thus presuming its increase with
progression of liver disease. 
Although an independent association between
liver steatosis/fibrosis and serum endocan level is
shown in the current study, this proteoglycan seems
to be more convenient in the diagnostic evaluation of
these liver disorders, in combination with other
markers, instead of its usage alone, as a single
biomarker. Namely, in our study endocan showed
poor discriminatory capability (AUC=0.648) for
NAFLD as a single predictor. On the contrary, when
tested in the Model [i.e., variables that entered the
Model were: gender, HbA1c, insulin, antihyper-
glycemic and antihypertensive therapies (categorical
variables), and HDL-c, ALT, hsCRP, endocan (contin-
uous variables)], endocan showed an excellent clini-
cal accuracy (AUC=0.930) with sensitivity of 90.58%
and specificity of 86.54%. 
We obtained the similar results when evaluating
the diagnostic accuracy of endocan in liver fibrosis.
Namely, endocan itself showed poor discriminatory
ability for advanced fibrosis (AUC=0.667). However,
when tested in the Model [i.e., variables that entered
the Model: gender, antihypertensive therapy (categor-
ical variables) and ages, TG, endocan (continuous
variables)], endocan showed an excellent discrimina-
tory capability (AUC=0.840) for advanced fibrosis,
with specificity of 86.36% and sensitivity of 72.41%. 
Our previous studies have also demonstrated
the benefits of multimarker approach in better dis-
crimination of individuals with liver steatosis (12–14).
Namely, an independent relationship between FLI
and insulin resistance (i.e. HOMA-IR) and inflamma-
tion (i.e. hsCRP) was recorded in the cohort of post-
menopausal women (13). Also, ALT was shown to be
independently correlated with FLI in both genders
(12) in a large Montenegrin population sample,
whereas HDL-c and malondialdehyde independently
correlated with FLI in the cohort of patients with type
2 diabetes mellitus (14). However, when tested in
model with other lipid, inflammation and oxidative
stress biomarkers, the discriminative ability for liver
steatosis development was significantly enhanced
(14). These mentioned results point out that in addi-
tion to traditional risk factors, multimarker approach
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patients with high risk of liver steatosis. Moreover, in
another study we have also reported that older age
and higher HDL-c are independently correlated with
advanced liver fibrosis assessed with the BARD score,
suggesting that further examination of enzymes
involved in lipoprotein metabolism could be per -
spective for revealing the causal association between
lipid parameters and liver fibrosis (16).
The main disadvantage of this study is its cross-
sectional design which limits us to conclude the
cause-effect between high endocan and liver
steatosis/fibrosis. Additionally, we were not able to
use imaging diagnostic procedures, but simple and
easy obtained algorithms, like previous studies did
(28, 33). However, the 2016 European Association
for the Study of the Liver (EASL), European
Association for the Study of Diabetes (EASD), and
European Association for the Study of Obesity
(EASO), recommended the usage of the FLI as one of
the best validated steatosis scores for screening stud-
ies in large samples (28). Additionally, BARD score is
shown to be useful for ruling out advanced fibrosis,
thus reducing the need for liver biopsies in NAFLD
patients (34, 35).
Conclusion
Higher serum endocan levels were observed in
NAFLD (as determined with FLI) and in advanced
fibrosis (as determined with BARD score), as
compared with controls. Importantly, endocan was
independently correlated with both, FLI and BARD
score. However, when tested in models (with other
biomarkers), this proteoglycan showed better discrim-
inatory ability for liver steatosis/fibrosis, instead of its
usage alone, as a single biomarker. 
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